Jun 18,2024

Real-World Data Reinforces Efficacy of Luminopia in Improving Vision for Patients with Amblyopia

Luminopia Inc. announced that real-world data from the Patients Using Prescription Luminopia (PUPiL) Registry™ continues to show the efficacy of its FDA-approved therapy for improving vision in children with amblyopia. The therapy combines therapeutic software with virtual reality (VR) headsets and popular children's TV shows. Data presented at the European and International Strabismological Association conference confirmed significant visual acuity improvements after 12 weeks of treatment, aligning with clinical trial results. The treatment, which avoids the compliance issues associated with traditional methods like eye patching and atropine drops, demonstrated high adherence and no safety events. This digital therapeutic uses dual-acting algorithms to encourage the brain to use both eyes together, providing a unique and effective alternative to conventional treatments.

CLINICAL STUDY

#virtual reality

#connected device

View Analyst & Ambassador Comments
Go to original news
Jun 21,2024

New MiniMed 780G system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes

Medtronic plc presented new data at the American Diabetes Association's 84th Scientific Sessions highlighting the benefits of its MiniMed 780G system. The system, equipped with an advanced algorithm providing autocorrections every 5 minutes, showed significant improvements in managing hyperglycemia and reducing nighttime disruptions for people with type 1 diabetes. A retrospective analysis of real-world data (n=6026) demonstrated a substantial decrease in dawn phenomenon rates from 12.2% to 4.5% when users transitioned from the MiniMed 770G to the MiniMed 780G system. Time in Range also increased significantly, from 87.7% to 91.4% from midnight to 6 a.m. The next iteration of the MiniMed™ 780G system, combined with the Simplera Sync™ sensor, showed promising results in clinical outcome metrics like Time in Range and Time Above Range compared to other delivery methods.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 13,2024

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

Glucotrack has announced the successful completion of a 60-day long-term preclinical study for its epidural continuous glucose monitoring sensor. The study demonstrated the sensor's ability to accurately monitor glucose levels in the epidural space, aligning closely with readings from traditional blood glucose monitors and subcutaneous CGMs. Throughout the study, no abnormal clinical signs or tissue reactions were observed, affirming the safety and reliability of the implanted sensor. Glucotrack plans to further develop this technology aimed at simplifying disease management for patients with painful diabetic neuropathy, potentially integrating it with existing treatments in the future.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 20,2024 TOP STORY

Economic Savings Model for Omada’s Cardiometabolic Programs

The study funded by Omada Health and conducted by Madison Noble, MPH, and Fang Chen, PhD, aimed to model the economic and health benefits of participating in virtual-first care (V1C) programs for cardiometabolic conditions. Using a microsimulation approach, the study focused on four types of programs: prevention, hypertension, diabetes, and diabetes plus hypertension. Participants showed sustained improvements in weight loss, hemoglobin A1c (HbA1c), and blood pressure (BP) levels, which were estimated to reduce disease onset by 2% to 10% over five years following enrollment. The study projected significant gross savings in healthcare expenditures. After one year, estimated savings ranged from $892 to $1342 per participant, with cumulative savings of $2963 to $4346 after three years, and $5221 to $7756 after five years.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 25,2024

Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1

DarioHealth Corp. announced new research showing that its digital platform supports sustained healthy behavior changes over 12 months for members taking GLP-1 medications for Type 2 diabetes. This retrospective study analyzed the data of 7,240 individuals with Type 2 diabetes using Dario to help manage their condition without the help of insulin for at least six months. The data, presented at the 84th Annual American Diabetes Association (ADA) Scientific Sessions, revealed that Dario's personalized approach led to significant improvements in blood glucose levels and increased healthy lifestyle activities. Additionally, 31% of Dario members achieved results consistent with diabetes remission, maintaining normal blood glucose levels without diabetic medications.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 19,2024 TOP STORY

AI could predict risk of lung cancer at an earlier stage, new research shows

Clinithink's AI technology has been instrumental in a pioneering project at Barts Health NHS Trust, funded by AstraZeneca, to predict lung cancer risk using patient medical records. Presented at the American Society of Clinical Oncology congress, the study leveraged AI to develop an algorithm that outperformed existing tools in identifying patients at higher risk of lung cancer. Analyzing over 75,000 patient records, the AI system demonstrated superior accuracy in predicting lung cancer compared to traditional risk assessment methods. This advancement could potentially lead to earlier detection and treatment of lung cancer, thereby improving survival rates. The success of this approach has prompted plans for prospective clinical trials to validate its effectiveness and potentially integrate it into the NHS's lung cancer diagnostic program.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Jun 06,2024

New study: Quantifying dosage in self-managed speech therapy

A new study by Boston University researchers, published in the American Journal of Speech-Language Pathology, used data from Constant Therapy’s app to validate the Cumulative Intervention Intensity (CII) framework for measuring speech therapy intensity in home-based settings. Analyzing data from 2,223 post-stroke survivors, the study confirmed CII's feasibility in self-managed contexts and identified three distinct user practice patterns.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 04,2019

Adding GAIA’s Digital Depression Therapy to Hospital Treatment Triples Remission Rates Over Six Months

A randomized controlled trial (RCT) demonstrated that incorporating GAIA's digital therapy software, deprexis, into standard inpatient hospital treatment significantly improved remission rates among patients with severe depression. The study, which included 229 patients, found that after six months, nearly three times as many patients achieved remission from depression when they used deprexis during their hospital stay. Secondary outcomes also showed significant improvements, including reductions in anxiety and enhancements in quality of life and self-esteem. These findings, led by Dr. Rüdiger Zwerenz and Professor Manfred Beutel at the University Medical Center Mainz, highlight the sustained therapeutic benefits of GAIA's digital treatments, which can be integrated into both inpatient and outpatient settings. The study was published in the Journal of Medical Internet Research.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 05,2024

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GlucoTrack, Inc. announced successful results from a 90-day preclinical study of its Continuous Blood Glucose Monitor (CBGM), demonstrating sustained accuracy with a Mean Absolute Relative Difference (MARD) of 4.7%, indicating high precision. The CBGM offers a simplified, discreet, and less intrusive method for continuous glucose monitoring, directly measuring blood glucose in real-time, unlike subcutaneous sensors. The study, which included more subjects and a longer duration than previous studies, validated the device's performance without significant adverse effects. GlucoTrack plans to start human clinical trials later this year, aiming to enhance the quality of life for people with diabetes by providing a convenient monitoring solution.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 18,2018

CytoReason’s unique immune-focused AI model creates the largest library of inter-cellular communications – uses it to predict 335 novel cell-cytokine interactions, new clues for drug development

CytoReason has achieved a groundbreaking milestone by leveraging its immune-focused AI model to create the largest library of inter-cellular communications. This achievement, published in Nature Biotechnology, involves analyzing 16 million scientific articles to quadruple the reference body of organized inter-cellular signaling interactions. This comprehensive analysis has led to the prediction of 335 novel cell-cytokine interactions, offering new insights for drug development. By standardizing and contextualizing the vast array of cell-cytokine relationships, CytoReason aims to enhance our understanding of the immune system and its role in disease mechanisms.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY